PubRank

Colin B Begg

Author PubWeight™ 132.85‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Computed tomography screening and lung cancer outcomes. JAMA 2007 8.01
2 Resurrecting treatment histories of dead patients: a study design that should be laid to rest. JAMA 2004 5.43
3 Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003 5.00
4 Survival of blacks and whites after a cancer diagnosis. JAMA 2002 4.27
5 Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med 2010 4.11
6 The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med 2003 4.01
7 Two-stage designs for gene-disease association studies. Biometrics 2002 3.67
8 Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol 2003 3.27
9 Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. J Urol 2005 2.98
10 Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003 2.85
11 Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann Surg 2002 2.71
12 Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006 2.42
13 One statistical test is sufficient for assessing new predictive markers. BMC Med Res Methodol 2011 2.24
14 Lack of effect of a low-fat, high-fruit, -vegetable, and -fiber diet on serum prostate-specific antigen of men without prostate cancer: results from a randomized trial. J Clin Oncol 2002 2.20
15 Two-stage designs for gene-disease association studies with sample size constraints. Biometrics 2004 2.08
16 Measuring complications of cancer treatment using the SEER-Medicare data. Med Care 2002 2.05
17 Reporting participation in case-control studies. Epidemiology 2002 1.99
18 Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002 1.93
19 The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. Cancer 2005 1.86
20 Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol 2010 1.85
21 Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res 2006 1.80
22 Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 2007 1.76
23 Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. J Surg Oncol 2003 1.73
24 Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology 2005 1.69
25 Attribution of deaths following cancer treatment. J Natl Cancer Inst 2002 1.63
26 Evaluating cancer epidemiologic risk factors using multiple primary malignancies. Epidemiology 2010 1.58
27 The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev 2006 1.51
28 Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res 2009 1.45
29 Ambient UV, personal sun exposure and risk of multiple primary melanomas. Cancer Causes Control 2007 1.44
30 Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size. Stat Med 2007 1.44
31 The use of hierarchical models for estimating relative risks of individual genetic variants: an application to a study of melanoma. Stat Med 2008 1.43
32 Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat 2010 1.40
33 Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol 2013 1.36
34 Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 2003 1.31
35 Hierarchical modeling for estimating relative risks of rare genetic variants: properties of the pseudo-likelihood method. Biometrics 2010 1.29
36 Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Hum Mutat 2012 1.26
37 Benchmarking lung cancer mortality rates in current and former smokers. Chest 2004 1.23
38 A metastasis or a second independent cancer? Evaluating the clonal origin of tumors using array copy number data. Stat Med 2010 1.18
39 Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst 2007 1.18
40 Comparing ROC curves derived from regression models. Stat Med 2012 1.15
41 CDKN2A germline mutations in individuals with cutaneous malignant melanoma. J Invest Dermatol 2007 1.14
42 Sun protection and skin self-examination in melanoma survivors. Psychooncology 2009 1.13
43 Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol 2012 1.13
44 Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat 2010 1.11
45 Estimating the empirical Lorenz curve and Gini coefficient in the presence of error with nested data. Stat Med 2008 1.07
46 Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling. Genet Epidemiol 2011 1.04
47 Vitamin D receptor polymorphisms in patients with cutaneous melanoma. Int J Cancer 2011 1.04
48 Comparison of properties of tests for assessing tumor clonality. Biometrics 2008 1.01
49 Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. Cancer Res 2008 1.00
50 Alcohol intake and cigarette smoking and risk of a contralateral breast cancer: The Women's Environmental Cancer and Radiation Epidemiology Study. Am J Epidemiol 2009 1.00
51 Taking stock of volume-outcome studies. J Clin Oncol 2003 0.99
52 Reproductive history and risk of second primary breast cancer: the WECARE study. Cancer Epidemiol Biomarkers Prev 2007 0.99
53 Clonality: an R package for testing clonal relatedness of two tumors from the same patient based on their genomic profiles. Bioinformatics 2011 0.98
54 Relationship between germline MC1R variants and BRAF-mutant melanoma in a North Carolina population-based study. J Invest Dermatol 2009 0.96
55 DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors. J Clin Oncol 2008 0.96
56 Evaluation of the clonal origin of multiple primary melanomas using molecular profiling. J Invest Dermatol 2009 0.96
57 Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers. J Natl Cancer Inst 2012 0.96
58 Associations of cumulative sun exposure and phenotypic characteristics with histologic solar elastosis. Cancer Epidemiol Biomarkers Prev 2010 0.95
59 Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. JAMA Oncol 2015 0.95
60 Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control 2015 0.94
61 Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas. Ann Surg Oncol 2011 0.94
62 Testing clonal relatedness of tumors using array comparative genomic hybridization: a statistical challenge. Clin Cancer Res 2010 0.93
63 Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study. JAMA Dermatol 2014 0.91
64 A comparison of methods to detect publication bias in meta-analysis by P. Macaskill, S. D. Walter and L. Irwig, Statistics in Medicine, 2001; 20:641-654. Stat Med 2002 0.91
65 Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report. Eur J Cancer 2013 0.90
66 MC1R genotype may modify the effect of sun exposure on melanoma risk in the GEM study. Cancer Causes Control 2010 0.90
67 Sun exposure, vitamin D receptor polymorphisms FokI and BsmI and risk of multiple primary melanoma. Cancer Epidemiol 2011 0.87
68 An assessment of estimation methods for generalized linear mixed models with binary outcomes. Stat Med 2013 0.87
69 Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Res 2012 0.87
70 Kin-cohort evaluation of relative risks of genetic variants. Genet Epidemiol 2003 0.86
71 Melanoma molecular subtypes: unifying and paradoxical results. J Invest Dermatol 2010 0.85
72 Using the Lorenz Curve to Characterize Risk Predictiveness and Etiologic Heterogeneity. Epidemiology 2016 0.84
73 Reflections on the landmark studies of beta-carotene supplementation. J Natl Cancer Inst 2004 0.83
74 HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case-control analyses. Breast Cancer Res Treat 2005 0.83
75 Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study. Cancer Causes Control 2010 0.82
76 Multiple imputation for correcting verification bias by Ofer Harel and Xiao-Hua Zhou, Statistics in Medicine 2006; 25:3769-3786. Stat Med 2007 0.82
77 Interaction of CDKN2A and sun exposure in the etiology of melanoma in the general population. J Invest Dermatol 2011 0.82
78 Inherited variation at MC1R and ASIP and association with melanoma-specific survival. Int J Cancer 2014 0.81
79 Comment on "the predictive capacity of personal genome sequencing". Sci Transl Med 2012 0.79
80 Disenrollment from Medicare managed care among beneficiaries with and without a cancer diagnosis. J Natl Cancer Inst 2008 0.78
81 A method for evaluating the impact of individual haplotypes on disease incidence in molecular epidemiology studies. Stat Appl Genet Mol Biol 2004 0.78
82 Letter to the editor of Biometrics. Biometrics 2007 0.78
83 Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: a population-based study. Carcinogenesis 2015 0.78
84 MITF E318K's effect on melanoma risk independent of, but modified by, other risk factors. Pigment Cell Melanoma Res 2014 0.77
85 Comments and response on the USPSTF recommendation on screening for breast cancer. Ann Intern Med 2010 0.77
86 Re: All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 2002 0.75
87 Marketing drugs too early in testing. Science 2006 0.75